169 related articles for article (PubMed ID: 2823821)
1. SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
Griswold DE; Marshall PJ; Webb EF; Godfrey R; Newton J; DiMartino MJ; Sarau HM; Gleason JG; Poste G; Hanna N
Biochem Pharmacol; 1987 Oct; 36(20):3463-70. PubMed ID: 2823821
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
Marshall PJ; Griswold DE; Breton J; Webb EF; Hillegass LM; Sarau HM; Newton J; Lee JC; Bender PE; Hanna N
Biochem Pharmacol; 1991 Jul; 42(4):813-24. PubMed ID: 1907824
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
Hanna N; Marshall PJ; Newton J; Schwartz L; Kirsh R; Dimartino MJ; Adams J; Bender P; Griswold DE
Drugs Exp Clin Res; 1990; 16(4):137-47. PubMed ID: 2127565
[TBL] [Abstract][Full Text] [Related]
4. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.
Horizoe T; Nagakura N; Chiba K; Shirota H; Shinoda M; Kobayashi N; Numata H; Okamoto Y; Kobayashi S
Inflamm Res; 1998 Oct; 47(10):375-83. PubMed ID: 9831321
[TBL] [Abstract][Full Text] [Related]
5. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
6. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
[TBL] [Abstract][Full Text] [Related]
7. Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro.
Votta BJ; Bertolini DR
Bone; 1994; 15(5):533-8. PubMed ID: 7980964
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivo.
Griswold DE; Marshall PJ; Lee JC; Webb EF; Hillegass LM; Wartell J; Newton J; Hanna N
Biochem Pharmacol; 1991 Jul; 42(4):825-31. PubMed ID: 1907825
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of inflammatory cell infiltration by bicyclic imidazoles, SK&F 86002 and SK&F 104493.
Griswold DE; Hoffstein S; Marshall PJ; Webb EF; Hillegass L; Bender PE; Hanna N
Inflammation; 1989 Dec; 13(6):727-39. PubMed ID: 2559032
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002.
Lee JC; Griswold DE; Votta B; Hanna N
Int J Immunopharmacol; 1988; 10(7):835-43. PubMed ID: 3148560
[TBL] [Abstract][Full Text] [Related]
11. The antiinflammatory action of guanabenz is mediated through 5-lipoxygenase and cyclooxygenase inhibition.
Chang J; Blazek E; Skowronek M; Marinari L; Carlson RP
Eur J Pharmacol; 1987 Oct; 142(2):197-205. PubMed ID: 3121363
[TBL] [Abstract][Full Text] [Related]
12. Arachidonic acid-induced inflammation: inhibition by dual inhibitor of arachidonic acid metabolism, SK&F 86002.
Griswold DE; Webb E; Schwartz L; Hanna N
Inflammation; 1987 Jun; 11(2):189-99. PubMed ID: 3108157
[TBL] [Abstract][Full Text] [Related]
13. Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro.
Boctor AM; Eickholt M; Pugsley TA
Prostaglandins Leukot Med; 1986 Aug; 23(2-3):229-38. PubMed ID: 3020588
[TBL] [Abstract][Full Text] [Related]
14. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
Li L; Ji H; Sheng L; Zhang Y; Lai Y; Chen X
Eur J Pharmacol; 2009 Apr; 607(1-3):244-50. PubMed ID: 19243697
[TBL] [Abstract][Full Text] [Related]
15. Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models.
Ku EC; Raychaudhuri A; Ghai G; Kimble EF; Lee WH; Colombo C; Dotson R; Oglesby TD; Wasley JW
Biochim Biophys Acta; 1988 Apr; 959(3):332-42. PubMed ID: 2833314
[TBL] [Abstract][Full Text] [Related]
16. 1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone(AHR-5333): a selective human blood neutrophil 5-lipoxygenase inhibitor.
Graff G; Anderson LA
Prostaglandins; 1989 Oct; 38(4):473-96. PubMed ID: 2554366
[TBL] [Abstract][Full Text] [Related]
17. 2-substituted indazolinones: orally active and selective 5-lipoxygenase inhibitors with anti-inflammatory activity.
Foster SJ; Bruneau P; Walker ER; McMillan RM
Br J Pharmacol; 1990 Jan; 99(1):113-8. PubMed ID: 2110012
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory effect of YPE-01, a novel diarylheptanoid derivative, on dermal inflammation in mice.
Yamazaki R; Aiyama R; Matsuzaki T; Hashimoto S; Yokokura T
Inflamm Res; 1998 Apr; 47(4):182-6. PubMed ID: 9628261
[TBL] [Abstract][Full Text] [Related]
19. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response.
Griswold DE; Webb EF; Breton J; White JR; Marshall PJ; Torphy TJ
Inflammation; 1993 Jun; 17(3):333-44. PubMed ID: 7687237
[TBL] [Abstract][Full Text] [Related]
20. Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
Griswold DE; Marshall P; Martin L; Webb EF; Zabko-Potapovich B
Agents Actions Suppl; 1991; 32():113-7. PubMed ID: 1906235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
